ASXL1 and myeloid neoplasm: Future efforts are warranted to investigate if ASXL1 mutation/dysregulation in the BM niche of patients contributes to the pathogenesis of myeloid malignancies, which will shed light on identifying novel therapeutic strategies for patients with ASXL1 alterations.